Abstract
Introduction Serum testosterone declines with age, such that 20-40% of men over 40 years old have low testosterone levels [1, 2] with 2-6% having symptoms of androgen deficiency and clinical hypogonadism. [3] [4] [5] Despite clinical guidelines recommending testosterone treatment only for men with symptomatic androgen deficiency and consistently low testosterone levels, [6] testosterone therapy has been used increasingly to treat men with a single low testosterone level. [7, 8] When initiated, testosterone treatment is often short-term, usually for an average of 16 months or less [9] [10] [11] [12] . Little is known about the safety of testosterone use in this clinical context. An increase in prostate specific antigen (PSA) within the first 12 months of initiating testosterone treatment [13, 14] , combined with the association between testosterone treatment and increases in prostate size, raises concerns about the possible increase in prostate cancer risk. [15] [16] [17] [18] Testosterone treatment could increase the near-term risk of prostate cancer by stimulating an occult tumor or it may impact risk over a longer period of time. Randomized trials that have been conducted to date have been underpowered to detect risk for prostate cancer. [19] [20] [21] [22] Meta-analyses of these testosterone treatment trials have not found increased risk of prostate cancer but have identified an increased risk for prostate biopsy.
We used data from the Veterans Health Administration (VHA) to determine if current patterns of testosterone use in Veterans are associated with adverse prostate cancer outcomes. We hypothesized that modest-duration testosterone treatment relative to no treatment is associated with an increase in prostate cancer risk and that, among testosterone users, a larger cumulative dose is associated with a higher risk.
Methods

Study design
We created an inception cohort study of men with low serum testosterone followed for initiation of testosterone treatment and incident aggressive prostate cancer. We utilized data from the United States Department of Veterans Affairs VHA, a large, electronically-integrated health care organization that provides medical care to eligible Veterans. The VHA Institutional Review Board approved this study.
Study cohort
Men aged 40-89 years with a laboratory-defined, low testosterone measurement who received outpatient care in any VHA facility between January 1, 2002 and December 31, 2011 , had at least 2 in-person VA clinic visits in the year prior to cohort entry, and PSA testing within 6 months of the low testosterone level (and prior to testosterone treatment) were eligible to enter the cohort (Appendix A). Cohort entry was the date of the first low testosterone level or the date of the qualifying PSA test, whichever occurred later. We excluded men with any history of testosterone treatment in the year prior to cohort entry, prevalent or past prostate or breast cancer, PSA ! 4.0 ng/dL, or a history of prostate biopsy.
We required that men survive one year following cohort entry because we assumed that there is increased potential for diagnosis of pre-existing prostate cancer in the first year [23] and that, if present, the effect of testosterone on prostate cancer progression exceeds one year. Men were followed until prostate cancer diagnosis, or censoring due to death, loss to followup (730 days after their last VA clinic visit), or end of study (September 30, 2012) .
Data sources
We collected data from two sources: the Corporate Data Warehouse (CDW), and the Veterans Affairs Central Cancer Registry (VACCR) (URL: https://www.hsrd.research.va.gov/for_ researchers/vinci/default.cfm; email: VINCI@VA.GOV).
The records obtained from these databases provided demographics, laboratory results and dates, prescription data, dates of clinic visit and hospitalizations, International Classification of Diseases ninth edition (ICD-9) diagnostic and procedure codes, and Current Procedural Terminology (CPT) procedure codes (Appendices A, B, and C).
Serum testosterone measurements
Serum testosterone tests were identified using the Logical Observation Identifiers Names and Codes (LOINC, see Appendix A). Men were classified as having low serum testosterone if they had a total testosterone, free testosterone, free/total testosterone, free testosterone index, or bioavailable testosterone test flagged as low in the reference range used by the specific testing laboratory and used by ordering providers in day-to-day clinical decision making.
Testosterone exposure
Testosterone prescriptions were identified using VA National Drug Internal Entry Numbers (IENs).
Data included the testosterone formulation (intramuscular injection, patch, or gel), initial prescription date, refill dates, dose, and amount dispensed (Appendices A and B). Treatment initiation was defined as the first prescription for testosterone following cohort entry. We assessed testosterone levels during treatment by averaging all levels measured after the initiation of treatment in testosterone-treated and after cohort entry in untreated men.
Two methods were used to model the association between time-varying testosterone exposure and prostate cancer risk: 1) Binary exposure where men were regarded as not treated until they received their first testosterone prescription and as treated thereafter, even if treatment was intermittent or later discontinued (analogous to an intention-to-treat analysis); and 2) Time-varying cumulative dose, calculated by summing the amount in mg of testosterone delivered (e.g., 5 gm dose of testosterone gel = 50 mg of testosterone applied = 5 mg of testosterone delivered) that was dispensed in all filled prescriptions.
Outcomes
The primary and secondary outcomes were the first occurrence of aggressive or any prostate cancer, respectively, between January 1, 2002 and September 30, 2012 . All prostate cancers were histologically confirmed in the VACCR which provided cancer histology, Gleason score, clinical stage, and PSA at the time of diagnosis (Appendix C). 
Medical comorbidities
Medical comorbidities were determined using ICD-9 diagnosis and procedure codes and CPT procedure codes, and medications and lab results that indicated specific conditions. A total of 26 medical conditions and hospitalization in the 365 days prior to cohort entry were determined a priori to characterize medical comorbidity (Appendix B, Table 1 ).
Statistical analysis
We performed Cox proportional hazards regression to estimate the adjusted associations of testosterone treatment with aggressive and any prostate cancer. Time-varying testosterone exposure was modeled: 1) as a dichotomous variable (treated/not treated) with follow-up starting one year after cohort entry; and 2) by cumulative testosterone dose during follow up in 5 categories among new testosterone users (1-399mg, 400-799mg, 800-1599mg, 1600-3199mg , and ! 3200mg), with follow-up starting one year after their first testosterone prescription. We performed baseline adjustment for age, race (White, Black, other), site of care, BMI, hospitalization in year prior to cohort entry, and 26 medical comorbidities (Table 1, Appendix B) and time-varying adjustment for medical comorbidities, repeated testosterone testing and PSA screening intensity.
We defined the "repeat testosterone level" variable as: repeated testosterone level low, repeated testosterone level not low or no repeat testosterone level. This measure was included because guidelines recommend at least two low testosterone levels prior to starting testosterone treatment. [6] Given the importance of PSA screening on the detection of prostate cancer, we assessed PSA testing across all years of study and we defined a time-varying "PSA screening intensity" variable as:: PSA screened in the last 6 months, screened in the last 6-12 months, or not screened in the last 12 months.
In analyses for aggressive and any prostate cancer, we adjusted for the number of comorbidities and presence/absence of individual comorbidities, respectively. In cumulative dose analyses, restricted to treated men, we adjusted for quintiles of the time from entry into the analytic cohort to treatment initiation to account for postponement of treatment.
Given that older men may be less likely to be screened for prostate cancer, we performed sensitivity analyses, where we separately considered men aged under 70 years at cohort entry and men aged 70 years or older at cohort entry. In secondary analyses, we considered the effect of testosterone exposure separately for intramuscular and topical treatment. Because prostate cancer initiation, progression, and clinical recognition are slow, we assessed the association of testosterone exposure with prostate cancer for men with a longer duration of follow-up by conducting two additional analyses: commencing follow-up at 3 and at 5 years after cohort entry.
Analyses were carried out using Stata Version 15. 
Results
We identified 301,003 men aged 40 to 89 with low testosterone flagged by the testing laboratory and with complete lab data. After a priori exclusions were applied, 147,593 (49%) men remained in the low-testosterone analysis cohort. During follow-up, 56,833 men initiated testosterone treatment (S1 Fig) . Most low testosterone measurements were total testosterone (80.9%) and free testosterone (14.5%). The median follow-up time for all men was 3.0 years (range, 1 day to 9.8 years) with 25% of men having follow up for > 5.9 years. Total follow-up time was slightly longer for treated men vs. untreated men (median, 3.2 vs. 2.8 years, respectively).
We identified 1,352,977 prescriptions for testosterone, of which 862,344 (63.7%) were intramuscular (IM), 361,644 (26.7%) were topical patches, and 128,989 (9.5%) were topical gels. Of the 56,833 men treated with testosterone, 22,738 (40.0%) were treated solely with IM testosterone, 21,746 (38.3%) solely with topical testosterone, and 12,349 (21.7%) with both. The mean cumulative duration of testosterone treatment was 27.0 (SD 27.3) months. The median cumulative duration of testosterone treatment was 17.3 (interquartile range (IQR) 6.6 to 36.8) months. The median number of PSA tests per year in testosterone treated and untreated men were 0.9 (IQR 0.4, 1.4) and 0.7 (IQR 0.0, 1.1) respectively.
There was a high burden of medical comorbidities at baseline among cohort members (Table 1) . There was little difference in the characteristics of men treated and not treated with testosterone, except sexual dysfunction, which was more prevalent among treated than untreated men (60% vs. 48%, respectively).
Repeat testosterone testing was more common among testosterone-treated men, with testosterone testing in 15,794 (69.5%) and 14,385 (66.2%) in IM-and topical-treated, respectively, versus 31,540 (35.5%) in untreated men. Untreated men had higher baseline testosterone levels than testosterone-treated men. At follow-up testosterone measurement, testosterone levels were higher among all men, including those who were untreated, and there was little difference in follow-up mean serum testosterone level between untreated and topical testosterone-treated men. However, IM testosterone-treated men had a mean serum testosterone level that was approximately 2-fold greater than that of untreated and topical testosterone-treated men ( Table 2 ).
Prostate cancer outcomes
Binary testosterone exposure: Treated vs. not treated. A total of 313 aggressive prostate cancer events were diagnosed. Among untreated men, there were 190 events (incidence rate (IR) 0.57 per 1000 person years, 95% confidence interval (CI) 0.49-0.65); among testosterone-treated men, there were 123 events (IR 0.58 per 1000 person years, 95% CI 0.48-0.69) ( Table 3 ). With baseline adjustment for age, race, care site, BMI, and recent hospitalization, and time-varying adjustment for medical comorbidities, repeated testosterone testing and PSA screening intensity, there was no difference in risk of aggressive prostate cancer in testosterone-treated versus untreated men: hazard ratio (HR) 0.89; 95% CI 0.70-1.13 (Table 4) .
A total of 1,439 any prostate cancers were diagnosed; 848 were diagnosed among untreated (IR 2.52 per 1000 person years, 95% CI 2.36-2.70) and 591 among testosterone-treated men (IR 2.78, 95% CI 2.56-3.01). In adjusted analyses, there was no difference in risk of any prostate cancer in testosterone-treated versus untreated men: HR 0.90; 95% CI 0.81-1.01.
Cumulative dose among testosterone-treated. In fully-adjusted analyses, there was no association between increasing cumulative testosterone dose and increasing risk of aggressive prostate cancer in testosterone-treated men. However, the highest (! 3200 mg) cumulative dose category was associated with a lower risk for aggressive prostate cancer (HR 0.34, 95% CI 0.18-0.64) and for any prostate cancer (HR 0.72, 95% CI 0.55-0.95) compared with the lowest dose category (1-399 mg) . (Table 4) . Type of testosterone: Intramuscular and topical formulations. Among IM-treated men, there was no increased risk for aggressive (adjusted HR 0.93; 95% CI 0.68-1.27) or any prostate cancer (adjusted HR 0.99; 95% CI 0.86-1.14), relative to untreated men (Table 5) . Cumulative dose of IM treatment was not associated with risk of aggressive prostate cancer (S1 Table) . It was also not associated with risk of any prostate cancer except the highest cumulative dose (HR 0.61, 95% CI 0.40-0.94) was associated with lower risk of any prostate cancer relative to the lowest dose (S2 Table) .
Among topically-treated men, there was no increased risk for aggressive (adjusted HR 0.92; 95% CI 0.67-1.26) or any prostate cancer (adjusted HR 0.85; 95% CI 0.73-1.00) relative to untreated men (Table 5 ). Cumulative dose of topical testosterone treatment was not associated with risk of aggressive or any prostate cancer (S1 and S2 Tables).
Sensitivity analyses, considering separately men who at cohort entry were aged under 70 years and men who were aged 70 years or older, yielded results consistent with those of the primary analyses. Sensitivity analyses that extended the survival requirement, commencing follow-up at 3 years and 5 years (58,763 men, with 20,776 treated, median follow-up 7.5 years) after cohort entry, also yielded results consistent with those of the primary analyses (Table 6 ).
Discussion
In analyses adjusted for time-varying medical comorbidities, repeat testosterone testing, and intensity of PSA monitoring, and that followed men for a median of 3.0 years, we observed that in men with low testosterone levels and normal PSA levels at baseline, testosterone treatment was not associated with increased incidence of aggressive or any prostate cancer compared with untreated men. Among men who initiated treatment, we found no evidence of increased aggressive or any prostate cancer risk with increasing cumulative dose of testosterone treatment, and when our analysis was limited to men who were treated only with intramuscular or topical (transdermal) testosterone. These findings are important given the rise in testosterone treatment and concerns for its potential associated risks. Given the association between testosterone treatment and increase in PSA levels and prostate biopsy, information on the near term risk of prostate cancer among this group of men is important for clinical decision making. In hypogonadal men, testosterone treatment increases prostate size and PSA. [15, 16] Exogenous testosterone has been shown to stimulate growth of metastatic prostate cancer, [24] and androgen-deprivation is used to treat metastatic and locally advanced prostate cancer. [18] However, it is unclear if testosterone treatment increases the risk for incident prostate cancer or if it alters the natural history of preexisting organ-confined prostate cancer. Recent meta-analyses of placebo-controlled testosterone treatment studies [19, 23, 25] found conflicting results on the association of testosterone treatment with prostate cancer risk.
Observational studies [10, 11, 26] found no increase in aggressive or any prostate cancer in testosterone-treated men but their conclusions were limited by the absence of an appropriate comparison group, lack of adjustment for PSA screening and lack of cumulative dosage analyses. A Swedish nested case-control study [9] found that testosterone treatment was associated with an increase in low and intermediate-risk prostate cancer during the first year of treatment and a decreased risk of aggressive prostate cancer. The former may be due to pre-existing prostate cancer that was detected due to PSA monitoring during initial testosterone treatment, a group that we intentially excluded form our analysis for this specific reason. While this study was the first to suggest that testosterone treatment was associated with a decreased risk for aggressive prostate cancer interpretation is challenging given the lack of data on testosterone levels and frequency of PSA assessment in both cases and controls. Nonetheless, results from our study are consistent with these findings in that among testosterone-treated men, those in the highest dose category (i.e. longest duration of therapy) demonstrated decreased risk for both aggressive and any prostate cancer compared with those in the lowest dose category. However, given few aggressive prostate cancers in the highest cumulative dose group and no consistent association of increasing testosterone dose with decreased risk for aggressive or any prostate cancer, we are reluctant to conclude that higher cumulative doses are associated with decreased aggressive prostate cancer risk. Our study cohort was selected to be similar to that of a clinical trial of testosterone treatment: no testosterone treatment in the prior year; no previous diagnosis of prostate or breast cancer; and a serum PSA level < 4 ng/dL. To control for potential differences between testosterone-treated and untreated men, we performed time-varying adjustments for 26 medical comorbidities, repeat testosterone testing, and the intensity of PSA screening as these factors may have affected the likelihood of being treated with testosterone and detecting prostate cancer.
We analyzed only men who survived one year after entering the cohort (binary testosterone exposure analysis) or one year after initiating testosterone treatment (cumulative dose analysis) because we assumed that testosterone treatment may lead to increased screening and detection of occult prostate cancer in the first year of treatment. We chose aggressive prostate cancer as the primary outcome because it is the most clinically impactful, leading to higher morbidity and mortality than non-aggressive prostate cancer. [27] 
Strengths and limitations
Our study is the largest pharmaco-epidemiologic study to examine the association between testosterone treatment and prostate cancer. Men were selected for having low testosterone levels and normal PSA levels, a population that is often treated with testosterone, although clinical manifestations of androgen deficiency were not available. A large number of prostate cancers were observed. Data were coded at clinical encounters, not through abstraction. Baseline testosterone and PSA were documented on all men and most treated men had follow-up testosterone and PSA levels. Many subjects received IM testosterone, which has more predictable bioavailability than topical testosterone. All prostate cancers were histologically-confirmed with tumor grade and stage assessment. Furthermore, we adjusted for repeat testosterone testing, PSA screening and changing medical comorbidity over time.
There are limitations of the study. Despite extensive adjustments, residual confounding is possible. We approached confounding adjustment in a time-dependent manner using 26 medical conditions. Alternative analytic methods, such as propensity scores that address the imbalance of characteristics in those who did and did not receive treatment, are possible, but with a large number of subjects and events, propensity scores do not to offer advantages over timedependent multivariable adjustment [28] . It is feasible that some men have been treated with testosterone outside of the VA, especially those men who are Medicare eligible. Given our inability to assess for non-VA prescribed testosterone use, these individuals may be miscategorized, therefore attenuating our results toward the null hypothesis. Because of the slow progression of prostate cancer, with autopsy studies suggesting that it may take 7-10 years for a prostate cancer to progress from indolent to aggressive, the isolation of men with longer follow-up time is desirable when assessing the risk of testosterone. In our study, median followup is 3 years, with the longest follow up time in our cohort being 9.8 years. However, sensitivity analyses that restricted the analytic cohort survival time to a minimum of five years were consistent with our primary analyses.
Conclusions
Among men with low testosterone and normal PSA levels who were followed for a median of 3 years, compared with untreated men, men treated with testosterone were not at increased risk of incident aggressive or any prostate cancer. The longer term clinical risks and benefits of testosterone treatment can only be definitively addressed by large, long-term randomized controlled trials. • ICD-9 (International Classification of Diseases ninth edition) codes for breast cancer in the year prior to cohort entry Codes used:
• ICD-9 codes: 174.xx, 175.xx
Exclude prevalent or past prostate cancer
Based on:
• ICD-9 codes for prostate cancer in the year prior to cohort entry
• CPT (Current Procedural Terminology) codes for prostate cancer treatment in the year prior to cohort entry
• Histologically-confirmed diagnosis of prostate cancer in the VACCR (VA Central Cancer Registry) in the year prior to cohort entry Codes used:
• ICD-9 codes: V10. 46, 60.4, 60.5, 60.52, 60.53, 60.62, 60.69, 185.xx, 233.4 • CPT codes: 55810, 55812, 55815, 55840, 55842, 55845, 55860, 55862, 55865, 55866, 55873, 55876 , 3269F, 3270F, 3271F, 3272F, 3273F, 3274F, 4163F, 4164F, 4201F, C1703, C1706, C1708, C1710, G0256, G0261, G9077, G9078, G9079, G9080, G9081, G9082, G9083, G9132, G9133
5. Exclude men with a history of prostate biopsy Based on:
• CPT codes for prostate biopsy
Codes used:
• CPT codes: 55700, 55705, 55706, 0137T, G0417, G0418, G0419
6. PSA value > 4.0 ng/dL Based on:
• LOINC (Logical Observation Identifiers Names and Codes) laboratory codes
• Used for exclusions only, not updated after baseline
• LOINC codes: 19195-7, 19197-3, 2857-1, 35741-8, 10886-0, 19201-3, 19203-9, 12841-3, 14120-0, 33667-7, 15323-9, 15324-7, 15325-4 7 . Testosterone level flagged as low Based on:
• LOINC laboratory codes
• Used for inclusion
• LOINC codes: 14913-8, 1639-4, 21555-8, 2986-8, 49041-7, 49042-7, 55519-3, 58835-0, 70239-9, 51005-7, 58716-2, 49042-5, 49043-3, 70240-7, 58952-3, 2990-0, 30123-4, 14914-6, 25987-9, 2991-8, 35225-2, 24125-7, 15432-8, 16286-7, 17686-7 Appendix B. Covariates
Age
Defined as:
• Age at time of cohort entry
• Divided into 5-year age categories (years)
• 40-44; 45-49; 50-54; 55-59; 60-64, 65-69; 70-74; 75-79; 80-84; 85+ • Not updated after baseline
Benign Prostatic Hyperplasia (BPH)
• ICD-9 codes
• IENs (VA National Drug Internal Entry Numbers) for alpha-blockers and 5 alpha-reductase inhibitors for BPH in the year prior to cohort entry Codes used:
• ICD-9 codes: 222.2x, 599.6x, 600.xx, 601.xx, 602.xx, 788.38, 788.41, 788.42, 788.43, 788.61-788.65, 788.69, 788.2x • IENs: 15938, 16325, 19649, 8293, 8294, 12741, 16660, 16661, 19648, 8291, 8295, 8838, 8840, 13685, 20071, 8290, 8292, 8837, 8839, 13610, 13611, 15721, 20070, 8296, 8297, 13634, 16128, 9712, 16129 , 9711
• 5 categories
• < 18.5
• 18.5-24.9
• 25.0-29.9
• 30.0-34.9
• ! 35
• BMI recorded closest to cohort entry date, with preference for prior to cohort entry
• Updated after baseline only with ICD-9 codes for obesity Codes used:
• ICD-9 codes: V85.4x, 278.01
Cardiac Arrhythmia
• ICD-9 codes: 426.xx, 427.xx
Cardiomyopathy
• ICD-9 codes: 425.xx 6. Cerebrovascular Disease (includes hard/soft outcomes)
• ICD-9 codes: 38. 11, 430.x, 431.x, 433.x1, 434.x1 7. Chronic Heart Failure Based on:
• ICD-9 codes: 428.xx, 398.91
Chronic Liver Failure
• ICD-9 codes: 456.0, 456. 1, 456.2x, 571.2, 571.3, 571.40, 571.41, 571.42, 571.49, 571.5, 571.6, 571.8, 571.9, 572.2, 572.3, 572.4, 572.8 9. Chronic Lung Disease
• ICD-9 codes: 491.2x, 492.xx, 493.xx (NOT 493.81 or 493.82), 496.xx
Chronic Pain
• IENs for long-acting opiates (methadone, long-acting morphine, fentanyl) in the 90 days prior to cohort entry Codes used:
• ICD-9 codes: 338.2x
• IENs: 142, 154, 15712, 15714, 160, 162, 17264, 20101, 378, 5800, 150, 15361, 156, 159, 21479, 387, 5799, 136, 147, 151, 152, 153, 15362, 155, 15703, 161, 163, 164, 165, 16557, 17697, 394, 396, 5801, 138, 139, 141, 143, 148, 149, 157, 15763, 158, 16556, 377, 5802 Based on:
• ICD-9 codes: 296.2x-296.3x
Malignancy
• ICD-9 codes: 140.xx-239.xx (NOT 140.xx, 173.xx, 174.xx, 179.xx, .xx)
Morbid Obesity
Osteoporosis
• ICD-9 codes: 733.00, 733.01, 733.02, 733.09
Peripheral Vascular Disease
• CPT codes
• ICD-9 codes: 38. 18, 38.19, 38.38, 38.39, 38.48, 38.49, 38.88, 38.89, 39.25, 39.26, 39.28, 39.29, 39.50, 39.90, 433, 433.9, 440.2x, 440.3x, 440.4x, 442.x, 443.x, 445.0x • CPT codes: 34800, 34802, 34803, 34804, 34805, 35226, 35256, 35286, 35351, 35355, 35371, 35372, 35381, 35454, 35456, 35459, 35473, 35474, 35482, 35483, 35485, 35492, 35493, 35495, 35546, 35548, 35549, 35551, 35556, 35558, 35563, 35565, 35566, 35571, 35583, 35585, 35587, 35646, 35656, 35661, 35663, 35665, 35666, 35671 23. Polycythemia
• LOINC laboratory codes for HCT > 52 in the year prior to cohort entry Codes used:
• ICD-9 codes: 289.0x
• LOINCs: 24360-0, 4544-3, 71833-8, 4545-0, 48703-3, 20570-8, 41655-2, 71830-4, 31100-1 24 . PSA (Prostate Specific Antigen) screening Defined as:
• 3 categories
• Not screened in the last 12 months
• Screened in the last 6-12 months
• Screened in the last 6 months Based on:
• Date of most recent PSA measure
• LOINC codes: 19195-7, 19197-3, 2857-1, 35741-8, 10886-0, 19201-3, 19203-9, 12841-3, 14120-0, 33667-7, 15323-9, 15324-7, 15325-4 25. Race 
